EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment



Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment



Analytical and Bioanalytical Chemistry 405(6): 1903-1911



Arsenic trioxide has been successfully used as a therapeutic in the treatment of acute promyelocytic leukemia (APL). Detailed monitoring of the therapeutic arsenic and its metabolites in various accessible specimens of APL patients can contribute to improving treatment efficacy and minimizing arsenic-induced side effects. This article focuses on the determination of arsenic species in saliva samples from APL patients undergoing arsenic treatment. Saliva samples were collected from nine APL patients over three consecutive days. The patients received 10 mg arsenic trioxide each day via intravenous infusion. The saliva samples were analyzed using high-performance liquid chromatography coupled with inductively coupled plasma mass spectrometry. Monomethylarsonous acid and monomethylmonothioarsonic acid were identified along with arsenite, dimethylarsinic acid, monomethylarsonic acid, and arsenate. Arsenite was the predominant arsenic species, accounting for 71.8 % of total arsenic in the saliva. Following the arsenic infusion each day, the percentage of methylated arsenicals significantly decreased, possibly suggesting that the arsenic methylation process was saturated by the high doses immediately after the arsenic infusion. The temporal profiles of arsenic species in saliva following each arsenic infusion over 3 days have provided information on arsenic exposure, metabolism, and excretion. These results suggest that saliva can be used as an appropriate clinical biomarker for monitoring arsenic species in APL patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 051637003

Download citation: RISBibTeXText

PMID: 23318765

DOI: 10.1007/s00216-012-6700-5



Related references

Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chemical Research in Toxicology 17(1): 95-103, 2004

Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment. Talanta 184: 446-451, 2018

Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Environmental Toxicology 28(5): 267-275, 2013

Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biological & Pharmaceutical Bulletin 29(5): 1022-1027, 2006

Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment. Leukemia Research 32(2): 357-358, 2007

Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leukemia Research 34(3): 403-405, 2010

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biology of Blood and Marrow Transplantation 15(11): 1479-1484, 2009

Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?. Leukemia & Lymphoma 55(5): 977-978, 2014

Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. Leukemia & Lymphoma 54(9): 2041-2046, 2014

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10): 3315-3324, 1999

Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 112(9): 3587-3590, 2008

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer ChemoTherapy and Pharmacology 59(4): 485-493, 2006

Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood 107(7): 3012-3013, 2006

Use of arsenic trioxide in the treatment of acute promyelocytic leukemia I Arsenic causes both apoptosis and partial differentiation of NB4 and fresh APL cells in vitro and vivo. Blood 88(10 SUPPL 1 PART 1-2): 219A, 1996

Treatment of de novo and relapsed acute promyelocytic leukemia patients with arsenic trioxide. Blood 92(10 SUPPL 1 PART 1-2): 678A, Nov 15, 1998